
|Articles|April 1, 2003
Imiquimod Benefits Kids Off-Label
Bal Harbour, Fla. - The use of topically applied immune response modifier imiquimod (Aldara) goes beyond its FDA-approved application for the treatment of genital and perianal warts.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
Introducing Dermatology Times NP/PA Connect
5











